Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Bruban

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceutica Acta Helvetiae|May 17, 2000
Imidazoline receptors: a challengeP Bousquet, V Bruban, S Schann, et al.
Hypertension (Dallas, Tex. : 1979)|March 7, 2001
Nitric oxide and central antihypertensive drugs: one more difference between catecholamines and imidazolinesG Y Sy, V Bruban, P Bousquet, et al.
Journal of the Autonomic Nervous System|December 16, 1998
Does a second generation of centrally acting antihypertensive drugs really exist?J Feldman, H Greney, L Monassier, et al.
Annals of the New York Academy of Sciences|July 23, 1999
Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugsP Bousquet, V Bruban, S Schann, et al.
Annals of the New York Academy of Sciences|March 19, 2004
I(1) imidazoline receptors involved in cardiovascular regulation: where are we and where are we going?P Bousquet, H Greney, V Bruban, et al.
Annals of the New York Academy of Sciences|July 23, 1999
An unexpected central hypertensive effect of the new imidazoline compound benazolineV Bruban, J Feldman, M Dontenwill, et al.
Journal of Medicinal Chemistry|May 4, 2001
Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I1 imidazoline receptor selective ligand with hypotensive activityS Schann, V Bruban, K Pompermayer, et al.
British Journal of Pharmacology|May 15, 2001
Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugsV Bruban, J Feldman, H Greney, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceutica Acta Helvetiae|May 17, 2000
Imidazoline receptors: a challengeP Bousquet, V Bruban, S Schann, et al.
Hypertension (Dallas, Tex. : 1979)|March 7, 2001
Nitric oxide and central antihypertensive drugs: one more difference between catecholamines and imidazolinesG Y Sy, V Bruban, P Bousquet, et al.
Journal of the Autonomic Nervous System|December 16, 1998
Does a second generation of centrally acting antihypertensive drugs really exist?J Feldman, H Greney, L Monassier, et al.
Annals of the New York Academy of Sciences|July 23, 1999
Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugsP Bousquet, V Bruban, S Schann, et al.
Annals of the New York Academy of Sciences|March 19, 2004
I(1) imidazoline receptors involved in cardiovascular regulation: where are we and where are we going?P Bousquet, H Greney, V Bruban, et al.
Annals of the New York Academy of Sciences|July 23, 1999
An unexpected central hypertensive effect of the new imidazoline compound benazolineV Bruban, J Feldman, M Dontenwill, et al.
Journal of Medicinal Chemistry|May 4, 2001
Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I1 imidazoline receptor selective ligand with hypotensive activityS Schann, V Bruban, K Pompermayer, et al.
British Journal of Pharmacology|May 15, 2001
Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugsV Bruban, J Feldman, H Greney, et al.
Pageof 1